NAFLD Clinical Trial
Official title:
Controlled Trial on the Effect of Tomato Products in Obese Children With Non Alcoholic Fatty Liver Disease
CONTROLLED TRIAL ON THE EFFECT OF TOMATO PRODUCTS IN OBESE CHILDREN WITH NON ALCOHOLIC FATTY
LIVER DISEASE
Aim of the study To evaluate the effect of the addition of a daily dose of lycopene enriched
tomato sauce on the progress of NAFDL in obese children.
Participants Children with obesity referred to the Hepatology unit of Dept.of Pediatric
Clinic of the University Federico II of Naples. Diagnosis of NAFLD is made on the presence of
fatty liver at ultrasound examination, with or without hypertransaminasemia.
Patients are eligible on the basis of:
- Age 4-14 years
- BMI > 85°percentile
- Liver Steatosis evaluated as mild, moderate or severe by US (hyperechogenic liver tissue
compared with the adjacent kidney cortex)
Patients are excluded on the basis of:
- Liver disease
- Diabetes or manifest metabolic alterations
- Associated diseases Informed consent is obtained from the parents of the participating
children. Sample size estimation To provide an 80% power to detect a 25% or greater
relative shift of outcome variables, with a first degree error of .05 a sample of 50
cases is estimated in a cross over trial.
Study design This is a randomized, crossover, one side open trial with blinded outcome
evaluation. A statistician who is not otherwise involved in the trial generated the
randomized assignment sequence. At the enrollment all participants received a low carotenoids
diet for two weeks (wash out), then children are assigned to the first intervention for 8
weeks, and subsequently, in the crossover phase, they are switched to the second intervention
for the next 8 weeks. No wash out is planned between the two treatments.
Interventions
1. Supplemented diet: 100 gr/day of Lycopene enriched tomato products (weekly average)
2. Control diet: ordinary healthy diet, with no special encouragement to eat carotenes
products All children are put on a 'mediterranean style' diet, with a controlled amount
of calories: a dedicated dietitian for the whole study, irrespective of the treatment,
checked their diet twice a week.
At beginning (T0) and at the end of each treatment (T1 and T2) all patients underwent
anthropomorphic measurements, including weight, height, waist, abdomen and hips
circumferences. BMI and its standard deviation score are calculated.
Regardless of group assignment, all participants are seen by a hepatologist at the end of
each intervention and checked for liver steatosis, by US. Fasting blood samples are collected
at beginning (T0) and at the end of each treatment (T1 and T2) to evaluate IR (assessed by
HOMA), transaminases levels, lipids profile, oxidative state (assessed by antioxidant enzymes
activity, serum levels of MDA and carbonylated proteins), inflammatory state (by cytokines
serum levels, typing of lymphocytes subpopulations, metabolism of lymphocytes).
Data collection are performed in a partially blind fashion: the statistician performing data
analysis is blind to treatment.
Outcomes: The primary outcome is reduction of the liver steatosis estimated by US Scan,
according to the following parameters: parenchyma echogenicity (compared with that of the
cortical of the right kidney), far gain attenuation, diaphragm blurring. steatosis.
Secondary outcomes is reduction in Insulin resistance, Oxidative state, Inflammatory state.
Statistical Analysis Data are inspected for normality and paired t-test (before/after) of
each phase of the trial are performed when appropriate. The Median % change of each variable
between the values at Time 8 and 16 weeks and values at enrollment are also looked. Ordinal
logistic regression analysis, hierarchical, mixed model with adjustment variables are adopted
to estimate the size of the effect.
The study is approved by the Ethical Committee of University Federico II of Naples.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06101433 -
The Effect of Soy Isoflavones on Non-alcoholic Fatty Liver Disease and the Level of FGF-21 and Fetuin A
|
N/A | |
Completed |
NCT03289897 -
Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan
|
N/A | |
Active, not recruiting |
NCT05479721 -
LITMUS Imaging Study
|
||
Completed |
NCT05527938 -
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
|
N/A | |
Recruiting |
NCT06308757 -
Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis
|
N/A | |
Completed |
NCT02654977 -
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
|
Phase 2 | |
Completed |
NCT02927184 -
Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
|
Phase 2 | |
Completed |
NCT06047847 -
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
|
N/A | |
Active, not recruiting |
NCT03534908 -
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study
|
||
Recruiting |
NCT06098417 -
Biomarkers in the Diagnosis and Prognosis of NAFLD
|
||
Recruiting |
NCT04564391 -
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
|
N/A | |
Not yet recruiting |
NCT05984745 -
Effect of CoQ10 on the Outcome of MAFLD Patients
|
Phase 2 | |
Not yet recruiting |
NCT05052515 -
The Effects of Natural Extracts Supplementation on NASH Patients
|
N/A | |
Recruiting |
NCT02459496 -
Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus
|
N/A | |
Completed |
NCT01936779 -
Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans
|
N/A | |
Completed |
NCT05844137 -
Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT04664036 -
Prevalence, Incidence and Characteristics of NAFLD/NASH in Type 1 Diabetes Mellitus
|
||
Recruiting |
NCT04976283 -
Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver
|
Phase 4 | |
Recruiting |
NCT03587298 -
Use of Shear Wave Elastography to Assess Non-alcoholic Fatty Liver Disease (NAFLD)
|
||
Completed |
NCT02952170 -
Impact of Weight Loss Surgery in Adolescents With NAFLD
|
N/A |